AN2 Therapeutics (ANTX)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ANTX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from AN2 Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$22M | -$41M | -$65M | -$51M | -$35M |
| Free cash flow | — | — | — | — | — |
| EPS (diluted) | -$10.64 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Operating margin | — | — | — | — | — |
Superinvestors who own ANTX
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by AN2 Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Margaret M Fitzpatrick Director |
2,098 | $5.53 | $11,602 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ANTX trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are AN2 Therapeutics insiders buying the stock?
1 open-market insider purchase of ANTX in the last 12 months, from SEC Form 4 filings.
Companies like AN2 Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.